MedTrace Logo

Multiple Myeloma Minimal Residual Disease

NCT02627261 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2022-09-06

No results posted yet for this study

Summary

Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease

Conditions

Interventions

BIOLOGICAL

blood samples and bone marrow aspirates will be collected

Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-23
Primary Completion
2018-09-02
Completion
2018-09-02

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02627261 on ClinicalTrials.gov